Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Elaine Willmore.

Newcastle AuthorsTitleYearFull text
Dr Carmela Ciardullo
Dr Katarzyna Szoltysek
Dr Peixun Zhou
Dr Elaine Willmore
Dr Amir Enshaei
et al.
Low BACH2 expression predicts adverse outcome in chronic lymphocytic leukaemia2022
Islam Al-Khawaldeh
Dr Christine Basmadjian
Dr Cinzia Bordoni
Dr Suzannah Harnor
Amy Heptinstall
et al.
An alkynylpyrimidine-based covalent inhibitor that targets a unique cysteine in NF-κB-inducing kinase (NIK)2021
Dr Timothy Barrow
Dr Elaine Willmore
Dr Gordon Strathdee
Dr Hyang-Min Byun
Analysis of retrotransposon subfamily DNA methylation reveals novel early epigenetic changes in chronic lymphocytic leukaemia2021
Dr Timothy Barrow
Dr Sirintra Nakjang
Kateryna Bilotkach
Dr Laura Woodhouse
Gesa Junge
et al.
Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia2021
Dr Wei-Yu Lin
Dr Sarah Fordham
Dr Nicola Sunter
Dr Claire Elstob
Dr Thahira Rahman
et al.
Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia2021
Dr Elaine Willmore
Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL2021
Dr Katarzyna Szoltysek
Dr Carmela Ciardullo
Dr Peixun Zhou
Dr Anna Walaszczyk
Dr Elaine Willmore
et al.
Dap kinase-related apoptosis-inducing protein kinase 2 (Drak2) is a key regulator and molecular marker in chronic lymphocytic leukemia2020
Dr Carmela Ciardullo
Erhan Aptullahoglu
Dr Laura Woodhouse
Dr Wei-Yu Lin
Dr Jonathan Wallis
et al.
Non-genotoxic MDM2 inhibition selectively induces pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells2019
Dr Catherine Willoughby
Huw Thomas
Dr Elaine Willmore
Suzanne Kyle
Dr Anita Wittner
et al.
Selective DNA-PKcs Inhibition Extends the Therapeutic Index of Localized Radiotherapy and Chemotherapy2019
Dr Celine Cano
Dr Suzannah Harnor
Dr Elaine Willmore
Professor Steve Wedge
Targeting DNA-PK as a Therapeutic Approach in Oncology2018
Dr Carmela Ciardullo
Dr Elaine Willmore
Dr Amir Enshaei
Dr Peixun Zhou
Dr Vikki Rand
et al.
BACH2 and BCL6 Cooperatively Fuction as Tumour Suppressors in CLL2016
Dr Carmela Ciardullo
Dr Elaine Willmore
Dr Peixun Zhou
Dr Vikki Rand
Professor Christine Harrison FRCPath FMedSci
et al.
Impact of the apoptotic regulator DRAK2 in chronic lymphocytic leukemia2016
Dr Carmela Ciardullo
Dr Peixun Zhou
Dr Elaine Willmore
Professor Christine Harrison FRCPath FMedSci
Emeritus Professor Andy Hall
et al.
Impact of the apoptotic regulator DRAK2 in chronic lymphocytic leukemia2016
Dr Timothy Barrow
Dr Laura Woodhouse
Gesa Junge
Dr Susan Tudhope
Dr Jonathan Wallis
et al.
The Role of HOXA4 in Chronic Lymphocytic Leukaemia Progression and Response to Therapy2016
Dr Laura Woodhouse
Clark Crawford
Dr Scott Marshall
Dr Nicholas Bown
Dr Elaine Willmore
et al.
Assessment and targeting of the MDM2-p53 network in CLL2015
Dr Elaine Willmore
Dr Aaron Ions Gardner
Dr Susan Tudhope
Belinda Murtani
Jessica Caffry
et al.
Novel small molecule IKK alpha inhibitors inhibit non- canonical NF-kappa B signaling and survival of primary CLL cells2015
Dr Ashleigh Herriott
Dr Susan Tudhope
Gesa Junge
Natalie Rodrigues
Dr Miranda Morton
et al.
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia2015
Laura Evans
Dr Lindi Chen
Dr Elaine Willmore
Professor Herbie Newell
Professor Deborah Tweddle
et al.
SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma2015
Andrew Shouksmith
Laura Evans
Professor Deborah Tweddle
Duncan Miller
Dr Elaine Willmore
et al.
Synthesis and Activity of Putative Small-​Molecule Inhibitors of the F-​Box Protein SKP22015
Emily Mould
Professor Herbie Newell
Dr Elaine Willmore
DNA-PK is activated by microtubule-targeting agents; mechanistic studies using isogenic wild-type and DNA-PK knockout cells2014
Emily Mould
Philip Berry
Dr David Jamieson
Dr Chris Hill
Dr Celine Cano
et al.
Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity2014
Pawel Znojek
Dr Elaine Willmore
Professor Nicola Curtin
Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase2014
Dr Alessio Iannetti
Dr Adeline Ledoux
Dr Susan Tudhope
Helene Sellier
Adam Moore
et al.
Regulation of p53 and Rb Links the Alternative NF-kappaB Pathway to EZH2 Expression and Cell Senescence2014
Emily Mould
Stephanie Burnell
Philip Berry
Professor Herbie Newell
Dr Elaine Willmore
et al.
The novel and contrasting roles of ATM and DNA-PK in the response of cells to microtubule-targeting anticancer agents2014
Emily Mould
Philip Berry
Dr David Jamieson
Dr Chris Hill
Niu Tan
et al.
The DNA-PK inhibitor, NU7441, sensitises cancer cells to microtubule-targeting agents and modulates vincristine efflux in multidrug resistant cells2013
Shilu Amin
Dr Meagan Walsh
Dr Caroline Wilson
Dr Elaine Willmore
Professor Derek Mann
et al.
Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL2012
Dr Elaine Willmore
Natalie Rodrigues
Dr Jonathan Wallis
Professor Nicola Curtin
High Activity of Poly(ADP-Ribose) Polymerase in Chronic Lymphocytic Leukemia2012
Dr Jill Hunter
Dr Elaine Willmore
Professor Julie Irving
Dr Stephany Veuger
Professor barbara Durkacz
et al.
NF-kappa B mediates radio-sensitization by the PARP-1 inhibitor, AG-0146992012
Dr Susan Tudhope
Dr Evan Mulligan
Dr Jill Hunter
Dr Helen Marr
Professor barbara Durkacz
et al.
P B S-1086, a "Pan-Rel" Inhibitor, Decreases Viability of Chronic Lymphocytic Leukemia Cells2012
Dr sarah Johnson
Clark Crawford
Dr Evan Mulligan
Dr Jonathan Wallis
Dr Tryfonia Mainou-Fowler
et al.
Mitoxantrone in combination with an inhibitor of DNA-dependent kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia2011
Dr Elaine Willmore
Dr Evan Mulligan
Dr Sarah Elliott
Professor barbara Durkacz
ATM Mutant Chronic Lymphocytic Leukaemia Cells are Chemosensitized by Inhibition of DNA Dependent Protein Kinase2010
Dr sarah Johnson
Dr Tryfonia Mainou-Fowler
Professor barbara Durkacz
Dr Elaine Willmore
Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: A potential therapy for poor risk B-cell chronic lymphocytic leukaemia2010
Dr Evan Mulligan
Arabella Baird
Dr Jonathan Wallis
Dr Stephany Veuger
Professor barbara Durkacz
et al.
Relationships Between Aberrant Activity of the NF-kappa B Subunits and Outcome In Chronic Lymphocytic Leukemia: The Dual Role of DNA Damage Sensor Enzymes2010
Dr Nicola Sunter
Dr Ian Cowell
Dr Elaine Willmore
Gary Watters
Professor Caroline Austin
et al.
Role of Topoisomerase IIbeta in DNA Damage Response following IR and Etoposide2010
Dr Miguel Lopez-Lazaro
Dr Elaine Willmore
Professor Caroline Austin
The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells2010
Dr Elaine Willmore
Dr sarah Johnson
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
Dr Celine Cano
et al.
DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia2008
Dr Elaine Willmore
Dr sarah Johnson
Clark Crawford
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
et al.
DNA-Dependent Protein Kinase Is a Therapeutic Target in Poor Prognosis B-Cell Chronic Lymphocytic Leukemia2008
Andrew Jobson
Dr Elaine Willmore
Dr Michael Tilby
Professor Caroline Austin
Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases2008
Dr Miguel Lopez-Lazaro
Dr Elaine Willmore
Dr sarah Johnson
Professor Caroline Austin
Selenite induces topoisomerase I and II-DNA complexes in K562 leukemia cells2008
Dr Miguel Lopez-Lazaro
Dr Elaine Willmore
Professor Caroline Austin
Cells lacking DNA topoisomerase IIβ are resistant to genistein2007
Dr Miguel Lopez-Lazaro
Dr Elaine Willmore
Andrew Jobson
Kathryn Gilroy
Hannah Curtis
et al.
Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells2007
Dr Elaine Willmore
Professor Graham Jackson
Dr Tryfonia Mainou-Fowler
Professor Caroline Austin
Professor barbara Durkacz
et al.
Sensitisation of B-CLL cells to chlorambucil and fludarabine via inhibition of the DNA damage sensor proteins, DNA-PK and ATM2006
Dr Elaine Willmore
Dr Tryfonia Mainou-Fowler
Professor Graham Jackson
Professor barbara Durkacz
Targeting DNA-PK and ATM increases sensitivity to chlorambucil and fludarabine in chemoresistant and p53-defective B-CLL cells2006
Lisa Smith
Dr Elaine Willmore
Professor Caroline Austin
Professor Nicola Curtin
The novel poly(ADP-ribose) polymerase inhibitor, AG14361 sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks2005
Dr Elaine Willmore
Dr Nicola Sunter
Dr Michael Tilby
Professor Graham Jackson
Professor Caroline Austin
et al.
A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia2004
Fiona Errington
Dr Elaine Willmore
Chrysoula Leontiou
Dr Michael Tilby
Professor Caroline Austin
et al.
Differences in the longevity of topo IIα and topo IIβ drug-stabilized cleavable complexes and the relationship to drug sensitivity2004
Dr Elaine Willmore
Professor Caroline Austin
Alchemix: A novel alkylating anthraquinone with potent activity against anthracycline- and cisplatin-resistant ovarian cancer2003
Dr Elaine Willmore
Professor Jeremy Lakey
Professor Caroline Austin
Characterisation of the DNA-dependent ATPase activity of human DNA topoisomerase IIß: mutation of Ser165 in the ATPase domain reduces the ATPase activity and abolishes the in vivo complementation ability2002
Andrew Jobson
Dr Elaine Willmore
Dr Michael Tilby
Professor Caroline Austin
Characterisation of the roles of Topoisomerase I and II in the mechanism of action of novel anti-tumour agents XR11576 (MLN576) and XR5944 (MLN944)2002
Dr Elaine Willmore
Fiona Errington
Dr Michael Tilby
Professor Caroline Austin
Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells2002
Dr Elaine Willmore
Dr Michael Tilby
Professor Caroline Austin
Professor barbara Durkacz
Potentiation of topoisomerase II poison cytotoxicity in the K562 human leukaemia cell line by the novel DNA-dependent protein kinase inhibitor NU70262002
Dr Elaine Willmore
Professor Caroline Austin
Professor Nicola Curtin
The role of poly(ADP-ribose) polymerase-1 (PARP-1) in the cellular response to topoisomerase I poisons2002
Fiona Errington
Dr Elaine Willmore
Dr Michael Tilby
Professor Caroline Austin
Murine transgenic cells lacking DNA topoisomerase IIβ are resistant to acridines and mitoxantrone: Analysis of cytotoxicity and cleavable complex formation1999
Dr Elaine Willmore
Dr Adrian Frank
Dr Kay Padget
Dr Michael Tilby
Professor Caroline Austin
et al.
Etoposide targets topoisomerase IIα and IIβ in leukemic cells: Isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique1998
Dr Ian Cowell
Dr Elaine Willmore
Dr David Allen Chalton
Professor Caroline Austin
Nuclear distribution of human DNA topoisomerase IIβ: A nuclear targeting signal resides in the 116-residue C-terminal tail1998
Dr Elaine Willmore
Dr Emma Meczes
Professor Caroline Austin
Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms α and β1996
Dr Elaine Willmore
Professor Caroline Austin
Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIα (p170) and IIβ (p180)1996
Professor Caroline Austin
Dr Elaine Willmore
Position-specific effects of base mismatch on mammalian topoisomerase II DNA cleaving activity1996
Professor Caroline Austin
Dr Elaine Willmore
Expression, domain structure and enzymatic properties of an active recombinant human DNA topoisomerase II beta1995
Dr Elaine Willmore
Professor barbara Durkacz
The effects of 5-fluoropyrimidines on nascent DNA synthesis in Chinese hamster ovary cells monitored by pH-step alkaline and neutral elution.1994
Dr Elaine Willmore
Professor barbara Durkacz
Cytotoxic mechanisms of 5-fluoropyrimidines: Relationships with poly(ADP-ribose) polymerase activity, DNA strand breakage and incorporation into nucleic acids1993
Dr Elaine Willmore
Professor barbara Durkacz
Correlation of enhanced 6-mercaptopurine cytotoxicity with increased phosphoribosylpyrophosphate levels in Chinese hamster ovary cells treated with 3-aminobenzamide1990